Eliem Therapeutics Reports Director Changes
Ticker: CLYM · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1768446
Sentiment: neutral
Topics: governance, board-changes
TL;DR
Eliem Therapeutics board shake-up, new director in, old one out.
AI Summary
Eliem Therapeutics, Inc. filed an 8-K on August 23, 2024, reporting the departure of a director and the election of a new director. The filing also details compensatory arrangements for certain officers. Specific names of the departing and newly elected directors are not provided in this excerpt, nor are the details of the compensatory arrangements.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is routine corporate governance and does not appear to involve significant financial transactions or operational changes.
Key Players & Entities
- Eliem Therapeutics, Inc. (company) — Registrant
- August 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1-877-ELIEMTX (phone_number) — Registrant's Telephone Number
FAQ
Who is the director that departed from Eliem Therapeutics?
The filing indicates the departure of a director but does not specify the name in the provided excerpt.
Who is the newly elected director at Eliem Therapeutics?
The filing states the election of a director but does not provide the name in the provided excerpt.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated August 23, 2024.
What is the principal executive office address for Eliem Therapeutics?
The address is PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE 19808-1609.
What is the SIC code for Eliem Therapeutics?
The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Stats: 936 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2024-08-27 17:21:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ELYM The Nasdaq Stock Mar
Filing Documents
- d884075d8k.htm (8-K) — 30KB
- d884075dex101.htm (EX-10.1) — 115KB
- 0001193125-24-207854.txt ( ) — 285KB
- elym-20240823.xsd (EX-101.SCH) — 3KB
- elym-20240823_lab.xml (EX-101.LAB) — 18KB
- elym-20240823_pre.xml (EX-101.PRE) — 11KB
- d884075d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Settlement Agreement, dated August 23, 2024, between Eliem Therapeutics, Inc. and Valerie Morisset, Ph.D. 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Eliem Therapeutics, Inc. Date: August 27, 2024 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer